Krystal expands commercial gene therapy production

January 28, 2020 -- Krystal Biotech on January 24 announced the beginning of construction on its second commercial gene therapy facility in Findlay Township in Pennsylvania. The facility will have the capacity to produce commercial gene therapy medicines for a variety of rare diseases.

The Current Good Manufacturing Practice (cGMP) facility, named ASTRA, expands on Krystal's current production capabilities, with in-house incorporation of raw material preparation, excipient manufacturing, testing, packaging, labeling, and distribution. ASTRA will fully integrate all components in the supply chain from starting materials to patient experience.

Over the next 12 to 15 months, validation throughout the 100,000-sq-ft space will occur. The state-of-the-art facility will initially be used as a commercial backup facility for bercolagene telserpavec (B-VEC), a gene therapy for treatment for dystrophic epidermolysis bullosa.

After the initial phase, Krystal plans to expand the use of the facility to produce investigational and commercial materials for its pipeline products. Upon opening, the facility will create 75 to 200 new jobs in biologics manufacturing.

Joint venture targets cell and gene therapy
A new joint venture dedicated to supporting researchers and biopharmaceutical companies in cell and gene therapy was announced on January 21. The joint...

Copyright © 2020

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter